Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat
- PMID: 2446629
- DOI: 10.1016/0006-2952(87)90565-x
Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat
Abstract
The influence of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on the central serotonergic and dopaminergic systems of the rat after a single or multiple injections was studied. MDE (10 mg/kg) produced a significant decrease in the concentration of 5-hydroxytryptamine (5-HT) 1 hr later in the frontal cortex and the hippocampus without affecting the concentration of 5-hydroxyindoleacetic acid (5-HIAA) or tryptophan hydroxylase (TPH) activity. Hypothalamic and neostriatal concentrations of 5-HT, 5-HIAA, dopamine (DA), dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) remained unaffected, as well as the neostriatal TPH and tyrosine hydroxylase (TH) activities. However, 3 hr after the MDE injection, the serotonergic variables including TPH activity were decreased in most of the brain areas examined. The dopaminergic system remained unaffected, except for a significant reduction in neostriatal DOPAC concentrations. The changes in transmitter concentrations after a single injection were dose dependent; the maximum depletion in TPH activity was reached with a 10 mg/kg dose. The administration of multiple doses of MDE caused greater decreases in TPH activity and 5-HT concentrations 3 hr after the treatment than did a single injection; in addition, a partial recovery from multiple administrations occurred by 18 hr. The effects of MDE on DA and its metabolites were transient, and neostriatal TH activity was not altered. This study demonstrates that MDE primarily affects the central serotonergic system, as reported for its congeners 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine. It does, however, produce less neurotoxicity as judged by its lower potency on the dopaminergic and the serotonergic systems as well as the recovery occurring in these systems.
Similar articles
-
Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system.Biochem Pharmacol. 1989 Dec 1;38(23):4333-8. doi: 10.1016/0006-2952(89)90534-0. Biochem Pharmacol. 1989. PMID: 2480796
-
A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives.Eur J Pharmacol. 1987 Feb 10;134(2):245-8. doi: 10.1016/0014-2999(87)90173-7. Eur J Pharmacol. 1987. PMID: 2883012
-
The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.Eur J Pharmacol. 1986 Aug 22;128(1-2):41-8. doi: 10.1016/0014-2999(86)90555-8. Eur J Pharmacol. 1986. PMID: 2875893
-
A review of the effects of repeated administration of selected phenylethylamines.Drug Alcohol Depend. 1986 Jun;17(2-3):143-50. doi: 10.1016/0376-8716(86)90005-0. Drug Alcohol Depend. 1986. PMID: 3017670 Review.
-
The role of serotonin in schizophrenia.Eur Neuropsychopharmacol. 1995;5 Suppl:11-23. doi: 10.1016/0924-977x(95)00027-m. Eur Neuropsychopharmacol. 1995. PMID: 8775754 Review.
Cited by
-
The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).CNS Drug Rev. 2004 Summer;10(2):89-116. doi: 10.1111/j.1527-3458.2004.tb00007.x. CNS Drug Rev. 2004. PMID: 15179441 Free PMC article. Review.
-
Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.Psychopharmacology (Berl). 1995 Apr;118(3):295-304. doi: 10.1007/BF02245958. Psychopharmacology (Berl). 1995. PMID: 7617822
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources